Jörg Wissel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jörg Wissel has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Djamel Bensmail
Department of Physical and Rehabilitation Medicine, Raymond-Poincaré Teaching Hospital, APHP, Université Paris-Saclay, 92380 Garches, France
8 shared publications Astrid Scheschonka
7 shared publicationsBirgit Flatau-Baqué
7 shared publicationsOlivier Simon
6 shared publicationsDavid Simpson
5 shared publicationsFranco Molteni
3 shared publications
Latest Publications
- Open Access
Correction: Tamayo et al. Botulinum Toxin in Pain-Related Post-Stroke Limb Spasticity: A Meta-Analysis of Early and Late Injections. Toxins 2025, 17, 258
In the original publication of this article
Open AccessCorrection: Tamayo et al. Botulinum Toxin in Pain-Related Post-Stroke Limb Spasticity: A Meta-Analysis of Early and Late Injections. Toxins 2025, 17, 258
In the original publication of this article
- Open Access
Botulinum Toxin in Pain-Related Post-Stroke Limb Spasticity: A Meta-Analysis of Early and Late Injections
Spasticity is a common complication associated with stroke, and around 72% of stroke patients will develop pain during the disease. Botulinum toxin (BoNT) is a safe and efficacious treatment for spasticity and can improve associated complications, including pain. Hence, this meta-analysis aims to establish whether BoNT can reduce pain-related post-stroke spasticity (pPSS) in the early treatment period (12 weeks post-stroke) based on the available evidence. This study also aims to establish the dose–response relationship of BoNT-A in pPSS. Based on pooled data from multiple studies, there is no significant difference in the scores measuring pPSS between patients who received early BoNT-A injections and those who received a placebo. This finding suggests that within the early treatment period, BoNT-A may not be more effective than a placebo in reducing pPSS. However, it is important to note that the data for early BoNT-A injections are limited, indicating that research is needed to draw definitive conclusions [z = 3.90 (p < 0.0001)]. While BoNT-A appears somewhat more effective than a placebo in the late phase, as indicated by the small to moderate positive z value, there is not enough evidence to confidently claim superiority over a placebo [z = 1.48 (p = 0.14)].
Open AccessBotulinum Toxin in Pain-Related Post-Stroke Limb Spasticity: A Meta-Analysis of Early and Late Injections
Spasticity is a common complication associated with stroke, and around 72% of stroke patients will develop pain during the disease. Botulinum toxin (BoNT) is a safe and efficacious treatment for spasticity and can improve associated complications, including pain. Hence, this meta-analysis aims to establish whether BoNT can reduce pain-related post-stroke spasticity (pPSS) in the early treatment period (12 weeks post-stroke) based on the available evidence. This study also aims to establish the dose–response relationship of BoNT-A in pPSS. Based on pooled data from multiple studies, there is no significant difference in the scores measuring pPSS between patients who received early BoNT-A injections and those who received a placebo. This finding suggests that within the early treatment period, BoNT-A may not be more effective than a placebo in reducing pPSS. However, it is important to note that the data for early BoNT-A injections are limited, indicating that research is needed to draw definitive conclusions [z = 3.90 (p < 0.0001)]. While BoNT-A appears somewhat more effective than a placebo in the late phase, as indicated by the small to moderate positive z value, there is not enough evidence to confidently claim superiority over a placebo [z = 1.48 (p = 0.14)].
- 1 October 2017
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 98 (10) , e63
Efficacy of IncobotulinumtoxinA in Treatment of Lower Limb Spasticity, Including Pes Equinovarus in Adults
- 1 October 2017
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 98 (10) , e63
Efficacy of IncobotulinumtoxinA in Treatment of Lower Limb Spasticity, Including Pes Equinovarus in Adults
- 1 October 2016
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 97 (10) , e10
Safety and Efficacy of Increasing Doses of IncobotulinumtoxinA (400U-800U) for Upper and Lower Limb Spasticity: The Phase III TOWER Study
- 1 October 2016
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 97 (10) , e10
Safety and Efficacy of Increasing Doses of IncobotulinumtoxinA (400U-800U) for Upper and Lower Limb Spasticity: The Phase III TOWER Study